


MOMENTUM IN OUR DYNAMIC PIPELINE BASED ON EMERGING DATA








1. Projected approval dates depend on data read-outs; some Wave 1 target approval dates assume accelerated approval
 2. Some Wave 2 assets could be accelerated into Wave 1 if they have breakthrough data

3. Approval date assumes filing on Phase 2 data
 4. Projected approval date evolving based on emerging data and study progress
 5. Revised program timelines will likely move approval date outside of Wave 1 timeframe

6. Expected new additions to the clinical pipeline with FPI projected in 1H FY20
 7. Wave 2 program with accelerated timeline
 8. Projected development in hepatic encephalopathy

All timelines are current best estimates and are subject to change due to impact by COVID-19 as of May 13, 2020

MAXIMIZING THE VALUE OF OUR APPROVED PROGRAMS

	PHASE 1 & 2	PHASE 3	FILED
 ONCOLOGY	<p>NINLARO® ● Proteasome inhibitor R/R MM triplet Tx (GL)</p> <p>ALUNBRIG® ● ALK inhibitor 2L ALK+NSCLC 2nd gen TKI (GL)</p> <p>ICLUSIG® ● BCR-ABL inhibitor TKI res. chronic phase CML (US)</p> <p>NINLARO® ● Proteasome inhibitor R/R MM doublet Tx (US, EU)</p>	<p>NINLARO® ● Proteasome inhibitor ND MM (GL)</p> <p>ALUNBRIG® ● ALK inhibitor 1L ALK+NSCLC (JP, CN)</p> <p>Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor 1L RCC combo w/nivolumab (JP)</p> <p>ICLUSIG® BCR-ABL inhibitor FL Ph+ ALL (US)</p> <p>NINLARO® ● Proteasome inhibitor Maint. ND MM no SCT (GL)</p> <p>ALUNBRIG® ALK inhibitor 2L ALK+NSCLC H2H with alectinib (GL)</p> <p>NINLARO® ● Proteasome inhibitor Maint. ND MM post-SCT (US, EU)</p>	<p>ADCETRIS® ● <i>Seattle Genetics</i> CD30 ADC R/R sALCL (CN)</p> <p>ADCETRIS® ● <i>Seattle Genetics</i> CD30 ADC R/R HL (CN)</p> <p>ALUNBRIG® ALK inhibitor ALK+NSCLC (JP)</p> <p>ALUNBRIG® ALK inhibitor 1L ALK+NSCLC (US)</p> <p>ADCETRIS® ● <i>Seattle Genetics</i> CD30 ADC 1L PTCL (EU)</p> <p>Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor 2L HCC (JP)</p> <p>Niraparib ●● <i>GlaxoSmithKline</i> PARP 1/2 inhibitor Ovarian cancer – maint. (JP)</p> <p>Niraparib ●● <i>GlaxoSmithKline</i> PARP 1/2 inhibitor Ovarian cancer – salvage (JP)</p>
 RARE DISEASES	<p>NATPARA PTH replacement Hypothyroidism (JP)</p>	<p>TAKHZYRO Anti-kallikrein mAb HAE pediatric (GL)</p> <p>OBIZUR ● <i>Ipsen</i> FVIII replacement CHAWI (US, EU)</p> <p>VONVENDI ● vWF replacement vWD Prophylaxis</p> <p>TAKHZYRO Anti-kallikrein mAb HAE (JP)</p> <p>VONVENDI ● vWF replacement vWD Pediatric</p> <p>ADYNOVATE Pediatric HemA (EU)</p>	<p>TAKHZYRO Anti-kallikrein mAb HAE prophylaxis (CN)</p>
 NEUROSCIENCE			<p>BUCCOLAM ● GABA Allosteric Modulator Status Epilepticus (JP)</p>
 GASTRO-ENTEROLOGY	<p>ENTYVIO® α4β7 mAb Pediatric UC/CD (GL)</p>	<p>GATTEX ● GLP-2R agonist Adult-SBS (JP)</p> <p>ALOFISEL® ● mesenchymal stem cells Perianal Fistulas in CD (US, JP)</p> <p>GATTEX ● GLP-2R agonist Pediatric-SBS (JP)</p> <p>Vonoprazan PCAB Oral disintegrated tablet formulation (JP)</p> <p>ENTYVIO® ● α4β7 mAb GvHD Prophylaxis (EU, JP)</p> <p>ENTYVIO® α4β7 mAb SubQ CD (US, JP)</p>	<p>ENTYVIO® α4β7 mAb SubQ UC (US, JP)</p> <p>Vonoprazan PCAB Reflex Esophagitis Maintenance (CN)</p> <p>Vonoprazan PCAB Duodenal ulcer (CN)</p>
 PLASMA-DERIVED THERAPIES		<p>CINRYZE ● PD C1 Esterase inhibitor HAE prophylaxis (JP)</p> <p>HYQVIA <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase CIDP</p> <p>HYQVIA ● <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase Pediatric PID (US)</p>	

Pipeline as of May 13, 2020; region abbreviations: GL = global (USA, Europe, Japan, China). Pipeline not all inclusive; programs also ongoing in other Therapeutic Areas

- Orphan Drug Designation (in any region / indication for a given asset)
- Potential for registration enabling Ph-2 study